Privium Fund Management B.V. Purchases 39,166 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

Privium Fund Management B.V. increased its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE) by 80.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 88,000 shares of the company’s stock after buying an additional 39,166 shares during the period. Privium Fund Management B.V.’s holdings in Wave Life Sciences were worth $1,089,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. KBC Group NV bought a new position in shares of Wave Life Sciences during the 4th quarter worth approximately $67,000. Point72 DIFC Ltd acquired a new position in shares of Wave Life Sciences during the 3rd quarter valued at $98,000. Orion Portfolio Solutions LLC bought a new position in Wave Life Sciences during the third quarter worth $123,000. XTX Topco Ltd acquired a new stake in Wave Life Sciences in the third quarter worth $126,000. Finally, Raymond James Financial Inc. bought a new stake in Wave Life Sciences in the fourth quarter valued at $157,000. Institutional investors and hedge funds own 89.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on WVE shares. StockNews.com raised shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Mizuho increased their price target on Wave Life Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a report on Wednesday, March 5th. Finally, Jefferies Financial Group started coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They set a “buy” rating and a $26.00 target price on the stock. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.60.

Wave Life Sciences Stock Down 3.7 %

WVE stock opened at $9.79 on Wednesday. The firm has a market capitalization of $1.50 billion, a PE ratio of -8.82 and a beta of -1.04. Wave Life Sciences Ltd. has a twelve month low of $4.25 and a twelve month high of $16.74. The stock’s 50 day moving average is $11.06 and its 200-day moving average is $11.50.

Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.34. The business had revenue of $83.75 million during the quarter, compared to analyst estimates of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. On average, equities research analysts anticipate that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Paul Bolno sold 169,025 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the transaction, the chief executive officer now directly owns 338,351 shares of the company’s stock, valued at $3,238,019.07. This represents a 33.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 29.10% of the stock is currently owned by corporate insiders.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.